Lung Cancer

Experts indicated that 77% of women with lung cancer who were surveyed reported having moderate to severe sexual dysfunction.

Closing out his discussion on actionable mutations in NSCLC, Roy Herbst, MD, PhD, discusses optimal sequencing of EGFR-targeted agents.

Considerations for use of novel EGFR-targeted agents osimertinib, amivantamab, and poziotinib in NSCLC, in the context of respective clinical trial data.

Roy Herbst, MD, PhD, provides insight on the importance of EGFR mutations, both common and rare, in patients with non–small cell lung cancer.

Expert perspectives on molecular profiling strategies that may help overcome barriers to testing in non–small cell lung cancer.

Expert oncologist Roy Herbst, MD, PhD, provides a comprehensive overview of actionable mutations and molecular profiling in NSCLC.

Before closing out his discussion on NSCLC, Sandip Patel, MD, shares his excitement for evolving targeted strategies and improved patient outcomes.

Focusing on the broader treatment armamentarium for EGFR-mutated NSCLC, Sandip Patel, MD, considers possible sequencing and combination strategies.

Sandip Patel, MD, highlights the use of afatinib and mobocertinib, respectively, to treat NSCLC with rare EGFR-mutation variants.

Insight on EGFR-mutated non–small cell lung cancer’s impact on treatment options and overall patient prognoses.

Expert perspectives on the current landscape of molecular profiling in patients with non–small cell lung cancer.

“Be courageous: Your work will be recognized, and everything is about [the] work in the end.”

Before closing out their discussion on non–small cell lung cancer, experts share excitement for possible improvements in the setting of perioperative therapy.

Experts consider when and if it would be appropriate to utilize targeted or immunotherapy in patients with EGFR exon 19 deletion–positive NSCLC.

Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.

A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.

Expert perspectives on the IMpower010 and KEYNOTE-091 trials, which assessed adjuvant immunotherapy in non–small cell lung cancer.

Shared insight on the CheckMate-816 trial and how immunotherapy may have a role in the neoadjuvant setting of non–small cell lung cancer.

A broad discussion on the role of immunotherapy in newly diagnosed NSCLC in both the neoadjuvant and adjuvant settings.

Shared insight on a patient profile of newly diagnosed non–small cell lung cancer with high PD-L1 expression and no driver mutation.

Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.

Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.

Anetumab ravtansine yielded a manageable safety profile in patients with relapsed mesothelin-positive malignant pleural mesothelioma in the second-line setting, but it did not appear to be superior to vinorelbine.

Although clinical trial enrollment declined among patients with lung cancer from 2019 to 2020 during the COVID-19 pandemic, mitigation strategies helped to improve enrollment.

Closing out their discussion on mobocertinib data and the EXCLAIM cohort, experts share hope for the future management of the EGFR exon 20 insertion–positive mNSCLC.